Uveal melanoma is a cancer of the eye. When it has spread to other parts of the body, it is typically treated with dacarbazine, but the cancer may persist or come back.
In this study, researchers want to see if adding the drug selumetinib to dacarbazine treatment is more effective than dacarbazine alone for patients with metastatic uveal melanoma. Selumetinib inhibits a protein called MEK, which is overactive in most uveal melanomas.
Patients in this study will be randomly assigned to receive dacarbazine plus selumetinib (three-quarters of the patients) or dacarbazine plus placebo (one-quarter of patients). Selumetinib is taken orally (by mouth), while dacarbazine is given intravenously (by vein). Patients whose cancers continue to grow despite dacarbazine/placebo will be able to switch to dacarbazine/selumetinib.